Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Gross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (2016 - 2026)

Ocular Therapeutix has reported Shares Outstanding over the past 14 years, most recently at $218.9 million for Q1 2026.

  • For Q1 2026, Shares Outstanding rose 37.44% year-over-year to $218.9 million; the TTM value through Mar 2026 reached $218.9 million, up 37.44%, while the annual FY2025 figure was $215.9 million, 36.88% up from the prior year.
  • Shares Outstanding for Q1 2026 was $218.9 million at Ocular Therapeutix, up from $215.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $218.9 million in Q1 2026 and troughed at $76.8 million in Q1 2022.
  • A 5-year average of $130.9 million and a median of $154.7 million in 2024 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: rose 0.53% in 2022 and later skyrocketed 99.58% in 2024.
  • Year by year, Shares Outstanding stood at $77.2 million in 2022, then soared by 48.91% to $115.0 million in 2023, then soared by 37.22% to $157.7 million in 2024, then skyrocketed by 36.88% to $215.9 million in 2025, then increased by 1.38% to $218.9 million in 2026.
  • Business Quant data shows Shares Outstanding for OCUL at $218.9 million in Q1 2026, $215.9 million in Q4 2025, and $174.9 million in Q3 2025.